Condition: Severe Hemophilia A Without Inhibitor · Sponsor: Tri-Service General Hospital (TSGH)
Study Objectives\* 1. Provide a systematic evaluation of the treatment outcomes in patients with hemophilia A 2. Emphasize the importance and clinical benefits of rFVIII-Fc in joint and bone health. 3. Compare the clinical outcomes from 1 year before and after switching to EHL. 4. Exploratory: Identify biomarkers that could provide more useful and convenient evaluations of joint and bone health. (Time-saving and easy to monitor)
This description comes directly from the study's public registry record.
Yeu-Chin Chen · (+886)2-87923311 · yeuchin99@gmail.com
Always discuss trial participation with your own doctor first.
| Tri-Service General Hospital Hemophilia Care Center | Taipei, Neihu Dist., Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05981274